Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
Top Cited Papers
- 1 January 2001
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 65 (2), 125-134
- https://doi.org/10.1023/a:1006478317173
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Hormone replacement therapy and accuracy of mammographic screeningThe Lancet, 2000
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast CancerAnnals of Internal Medicine, 1999
- Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal DensityAnnals of Internal Medicine, 1999
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialThe Lancet, 1998
- Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised womenThe Lancet, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Molecular basis of agonism and antagonism in the oestrogen receptorNature, 1997
- Bone Mineral Density and Risk of Breast Cancer in Older WomenJama-Journal Of The American Medical Association, 1996